Respiporc FLUpan H1N1

RSS

inactivated influenza A virus/humanstrain: A/Jena/VI5258/2009(H1N1)pdm09

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Respiporc FLUpan H1N1. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Respiporc FLUpan H1N1.

For practical information about using Respiporc FLUpan H1N1, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 07/12/2018

Authorisation details

Product details
Name
Respiporc FLUpan H1N1
Agency product number
EMEA/V/C/003993
Active substance
inactivated influenza A virus/humanstrain: A/Jena/VI5258/2009(H1N1)pdm09
International non-proprietary name (INN) or common name
inactivated influenza A virus/humanstrain: A/Jena/VI5258/2009(H1N1)pdm09
Species
Pigs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AA03
Publication details
Marketing-authorisation holder
IDT Biologika GmbH
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
16/05/2017
Contact address
Am Pharmapark
06861 Dessau-Rosslau
Germany

Product information

13/09/2018 Respiporc FLUpan H1N1 - EMEA/V/C/003993 - II/0004

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals
  • Inactivated viral vaccines for pigs

  • porcine influenza virus

Therapeutic indication

Active immunisation of pigs from the age of 8 weeks onwards against pandemic H1N1 porcine influenza virus to reduce viral lung load and viral excretion.

Assessment history

How useful was this page?

Add your rating